drugset / Trial / NCT04598204

Efficacy and Safety of Rapamycin to Complex Vascular Anomalies in Pediatric Patients

NCT04598204

Phase 2/3 Unknown 30 enrolled Zhujiang Hospital
NaSingle-groupOpen-labelTreatment

Summary

KHE and TA are rare tumors and some of the cases may lead to life-threatening complications including Kasabach-Merritt Phenomenon. Typically treated with steroids and vincristine, a majority of the cases do not have good prognosis. Complex vascular malformations are always managed by surgery,sclerotherapy and embolization therapy. While many of the cases still lead to complications such as disfigurement, chronic pain, recurrent infections, coagulopathies. Different medical centers are exploring new therapy for these tough problems. This study is plotted to determine the efficacy and safety of rapamycin monotherapy in KHE/TA and complex vascular malformations in pediatric patients.

Timeline

Start
2017-12-01
Primary completion
2022-12-01
Completion
2022-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Sirolimus Small molecule 0.8 mg/m2 Oral

Indications